<DOC>
	<DOC>NCT01164696</DOC>
	<brief_summary>The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population receiving 90Y-Zevalin, with model-predicted data at reimbursement on the basis of a clinical trial in heavily pre-treated NHL.</brief_summary>
	<brief_title>A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Advanced cancer of the lymph nodes of follicular type at study inclusion The patient has relapsed or has refractory disease, after previous treatment with rituximab Treating physician has decided to treat the patient with a 90YZevalin regimen The patient is &gt;= 18 years of age Patient has given informed consent Patient is unwilling or unable to give informed consent Patient is participating in another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Quality of Life, Health Care Costs</keyword>
</DOC>